Clinical Trial

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 4, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.
Trial Details
NCT Number NCT07154342
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions Allergic Rhinitis, Seasonal
Enrollment 150 participants
Start Date 2025-08-15
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-04